The DRUG Access Protocol: access inequality and European harmonisation - Authors' reply

Lancet Oncol. 2022 May;23(5):e203. doi: 10.1016/S1470-2045(22)00210-8.

Authors

Sahar Barjesteh van Waalwijk van Doorn-Khosrovani¹, Laurien J Zeverijn², Emile E Voest³

Affiliations

¹ CZ Health Insurance, Tilburg, Netherlands.
² Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX, Amsterdam, Netherlands; Oncode Institute, Utrecht, Netherlands.
³ Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX, Amsterdam, Netherlands; Oncode Institute, Utrecht, Netherlands. Electronic address: e.voest@nki.nl.

PMID: 35489347
DOI: 10.1016/S1470-2045(22)00210-8

No abstract available

Publication types

Letter
Comment

MeSH terms

Humans
Socioeconomic Factors*